Annovis Bio
Update in progressANVS (NYSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Annovis Bio, Inc. is a clinical-stage drug development company focused on neurodegenerative diseases in the United States. Its lead candidate, Buntanetap, is in Phase 3 for Alzheimer's disease and in an open-label Phase 3 for Parkinson’s disease. The company also develops ANVS405, in Phase 2/3 trials for traumatic brain injury and/or stroke, and ANVS301, which completed Phase 1 to improve cognitive function in later-stage Alzheimer’s and dementia. Founded 2008, based in Malvern, Pennsylvania.
Company score
- Sentiment
- 0.26
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.19
- Governance
- 0.09
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.17
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNYSE (NYQ)
- LocationUnited States
- CEODr. Maria L. Maccecchini Ph.D.
- Founded2008
- Employees7
- Websitewww.annovisbio.com
Identifiers
- ISINUS03615A1088
- FIGIBBG00PN9XD40
- LEI549300IFBVI51FN3NJ32
- CUSIP03615A108
- CIK0001477845